Abstract
In ARL, rituximab may slightly improve CHOP response but is associated with greater toxicity (
Proc Am Soc Hem
102
:1488
, 2003
BLOOD
101
:4653
, 2003
Author notes
Corresponding author
2005, The American Society of Hematology
2004
Advertisement intended for health care professionals
Kieron Dunleavy, Richard Little, Juan Gea-Banacloche, Nicole Grant, Seth Steinberg, Robert Yarchoan, Stefania Pittaluga, Elaine Jaffe, John Janik, Wyndham H. Wilson; Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL).. Blood 2004; 104 (11): 3111. doi: https://doi.org/10.1182/blood.V104.11.3111.3111
Download citation file:
In ARL, rituximab may slightly improve CHOP response but is associated with greater toxicity (
Corresponding author
Advertisement intended for health care professionals
Advertisement intended for health care professionals
Advertisement intended for health care professionals
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal